Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 May 2019
Historique:
received: 15 04 2019
revised: 10 05 2019
accepted: 13 05 2019
entrez: 22 5 2019
pubmed: 22 5 2019
medline: 13 11 2019
Statut: epublish

Résumé

The aim of this study was to investigate the predictive value of blood-derived makers of local and systemic inflammatory responses on early and long-term oncological outcomes. A retrospective analysis of patients with locally advanced rectal cancer treated with preoperative long-course 5-fluorouracil-based radiochemotherapy was performed. Differential blood counts before neoadjuvant treatment were extracted from the patients' electronic charts. Optimal cut-off values for neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were determined. Potential clinical and hematological prognostic factors for disease-free survival (DFS) were studied using uni- and multivariate analysis. A total of 220 patients were included in the analysis. Median follow-up was 67 months. Five-year DFS and overall survival (OS) were 70% and 85%, respectively. NLR with a cut-off value of 4.06 was identified as optimal to predict DFS events. In multivariate analysis, only tumor volume (HR 0.33, 95% CI (0.14-0.83),

Identifiants

pubmed: 31108935
pii: ijms20102448
doi: 10.3390/ijms20102448
pmc: PMC6566677
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Ann Surg. 1992 Jun;215(6):696-705; discussion 705-6
pubmed: 1632690
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Med Res Rev. 2011 May;31(3):311-63
pubmed: 19967776
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Semin Cancer Biol. 2012 Feb;22(1):33-40
pubmed: 22210179
PLoS One. 2012;7(1):e30806
pubmed: 22295111
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Oncol Rep. 2012 Aug;28(2):453-8
pubmed: 22614133
Cancer Immunol Immunother. 2012 Aug;61(8):1155-67
pubmed: 22692756
Colorectal Dis. 2012 Oct;14(10):e701-7
pubmed: 22731833
Semin Cancer Biol. 2013 Jun;23(3):200-7
pubmed: 23403174
Oncology. 2013;85(1):27-32
pubmed: 23816828
Front Oncol. 2013 Oct 07;3:262
pubmed: 24109590
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
BMC Surg. 2014 Nov 18;14:94
pubmed: 25406793
Radiat Oncol. 2014 Dec 18;9:295
pubmed: 25518933
Radiat Oncol. 2015 Jun 04;10:124
pubmed: 26040453
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Int J Hyperthermia. 2016;32(2):187-92
pubmed: 26754458
Immunol Cell Biol. 2017 Apr;95(4):325-332
pubmed: 27999432
Med Sci Monit. 2017 Jan 19;23:315-324
pubmed: 28100902
J Surg Oncol. 2017 Mar;115(4):470-479
pubmed: 28105646
Clin Transl Radiat Oncol. 2017 Mar 23;3:9-15
pubmed: 29658007
Sci Rep. 2018 May 15;8(1):7565
pubmed: 29765096
Oncotarget. 2018 Apr 27;9(32):22368-22382
pubmed: 29854285
Tumori. 2018 Aug 17;:300891618792476
pubmed: 30117371
J Surg Res. 2018 Dec;232:275-282
pubmed: 30463730
Cancer Manag Res. 2018 Dec 24;11:191-199
pubmed: 30636893
World J Gastroenterol. 2019 Jan 7;25(1):118-137
pubmed: 30643363
Radiother Oncol. 2019 Feb;131:52-59
pubmed: 30773187
Int J Cancer. 2019 Mar 14;:null
pubmed: 30868576
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Int J Colorectal Dis. 1997;12(1):19-23
pubmed: 9112145

Auteurs

Lore Helene Braun (LH)

Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany. helene.braun@med.uni-tuebingen.de.

David Baumann (D)

Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany. David.baumann@med.uni-tuebingen.de.

Kerstin Zwirner (K)

Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany. Kerstin.zwirner@med.uni-tuebingen.de.

Ewald Eipper (E)

Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, 72076 Tübingen, Germany. ewald.eipper@med.uni-tuebingen.de.

Franziska Hauth (F)

Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany. Franziska.hauth@med.uni-tuebingen.de.

Andreas Peter (A)

Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, 72076 Tübingen, Germany. Andreas.peter@med.uni-tuebingen.de.

Daniel Zips (D)

Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany. Daniel.zips@med.uni-tuebingen.de.
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. Daniel.zips@med.uni-tuebingen.de.
Gastrointestinal Cancer Center, Comprehensive Cancer Center Tübingen-Stuttgart, 72076 Tübingen, Germany. Daniel.zips@med.uni-tuebingen.de.

Cihan Gani (C)

Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany. cihan.gani@med.uni-tuebingen.de.
German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany. cihan.gani@med.uni-tuebingen.de.
Gastrointestinal Cancer Center, Comprehensive Cancer Center Tübingen-Stuttgart, 72076 Tübingen, Germany. cihan.gani@med.uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH